Asia-Pacific Veterinary Healthcare market Segmented by products, Veterinary diagnostic technologies, Veterinary genetics, by animal types Trends & Forecasts (2017 - 2022)

The Asia-Pacific veterinary healthcare market, estimated at USD 4.75 billion in 2014, is set to reach USD 10.6 billion by 2020, with a CAGR of 14.33% over the forecast period.

The veterinary healthcare market is gaining importance as a result of manufacturers focusing on the production of products with specialized formulations and manufacturing processes. The importance of livestock animals is generating growth in the animal healthcare market as a result of more people consuming meat and dairy products. The population boom and the stable economy are expected to result in increased demand for protein-rich foods, especially in developing regions. Animal health companies are well-positioned to address this growing emerging market demand for higher-protein diets.

Asia-Pacific Veterinary Healthcare Market- Market Dynamics

The new types of diseases in animals and their subsequent transfer to humans via animal food product consumption and companionship are escalating the veterinary healthcare industry in the Asia-Pacific region. The strategic decisions in research and development of manufacturers are expected to positively impact Asia-Pacific veterinary healthcare market.


Some of the factors driving market growth in this region are:

Increased love for pets leading to increased ownership

More awareness for animal health

Fewer requirements for animal health drugs approval

Continuous innovations and technological advances in development of animal health drugs

Improved nutrition

Intensifying consumer focus on food safety

Greater livestock production rates

Increasing foodborne diseases

Need to increase production of farm animal products (eggs, milk, beef and other dairy products)


The market has the following restraining factors:

Scarcity of arable land and water

Increased competition for cultivated land

Cost-effective production

In this report, the Asia-Pacific veterinary healthcare market is discussed in detail with segmentation by animal products (vaccines, parasiticides, anti-infectives, medicinal feed additives and other pharmaceuticals), animal types (companion animals, farm animals), animal diagnostic market, animal genetics market geography (China, Japan, India, South Korea, Australia and Others)

Some of the key players in the market are:

Bayer Healthcare

Boehringer Ingelheim

Ceva Animal Health, Inc.



Merial (Animal Health Division of Sanofi)


What the Report Offers

Market definition for the Asia-Pacific veterinary healthcare market along with identification of key drivers and restraints for the market.

Market analysis for the Asia-Pacific veterinary healthcare market, with region-specific assessments and competition analysis on a global and regional scale.

Identification of factors instrumental in changing the market scenario, rising prospective opportunities and identification of key companies that can influence the market on a global and regional scale.

Extensively researched competitive landscape section with profiles of major companies along with their strategic initiatives and market share.

Identification and analysis of the macro and micro factors that affect the Asia-Pacific veterinary healthcare market on both global and regional scale.

A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.

The report provides competitive intelligence analysis in the form of mergers and acquisition activity, collaborations, agreements, new product launches along with the profiles of major players.


1.1 Market Definition

1.2 Market Recent Trends

2 Market Analysis

2.1 Market Animal Health Products

2.2 Animal medicines vs human Medicines

3. Market Dynamics

3.1 Market Drivers

3.1.1 Increase in pet ownership

3.1.2 Improved Nutrition

3.1.3 Intensifying consumer focus on food safety

3.1.4 Greater Livestock production

3.1.5 Increasing Zoonotic and Foodborne Diseases

3.2 Market Constraints

3.2 1 Scarcity of arable land and water

3.2.2 Increased competition for cultivated land

3.2.3 Cost-effective production

3.3 Porter's Five Force Analysis

3.3.1 Threat of New Entrant

3.3.2 Internal Rivalry

3.3.3 Buyer bargaining power

3.3.4 Supplier bargaining power

3.3.5 Threat of substitutes

4. Asia-Pacific Veterinary healthcare Market Segmentation- Animal Types, based on products

4.1 Companion Animal health

4.1.1 Vaccines

4.1.2 Parasiticides

4.1.3 Anti-Infectives

4.1.4 Medicinal Feed Additives

4.1.5 Other Pharmaceuticals

4.2 Farm Animal health

4.2.1 Vaccines

4.2.2 Parasiticides

4.2.3 Anti-Infectives

4.2.4 Medicinal Feed additives

4.2.5 Other Pharmaceuticals

5. Asia-Pacific Veterinary Diagnostics Market

5.1 Enzyme Linked Immuno Sorbent Assay (ELISA)

5.2 Rapid Immuno Migration (RIM)

5.3 Agar gel Immuno Diffusion (AGID)

6. Asia-Pacific Veterinary Genetics Market

6.1 HD 50K for Angus

6.2 CLARIFIDE ? for Dairy

6.3 Sheep 50K

6.4 CLARIFIDE ? for Nelore

6.5 Others

7. Asia-Pacific Veterinary Healthcare Market Segmentation- By Animal Species

7.1 Farm animal

7.1.1 Cattle

7.1.2 Swine

7.1.3 Poultry

7.1.4 Fish

7.1.5 Sheep

7.2 Companion Animals

7.2.1 Dogs

7.2.2 Cats

7.2.3 Horses

8. Asia-Pacific Veterinary healthcare market- Country-level Analysis

8.1 India

8.2 China

8.3 Japan

8.4 Rest of APAC

9. Competitive landscape

9.1 Major players in the market

9.2 Mergers and acquisitions

9.3 New product launches

9.4 Agreement, Collaborations, and Partnerships

9.5 Recommendations for New players

9.6 Recommendations for Existing players

10. Company profiles

10.1 Zoetis Animal Healthcare

10.1.1 Financial Overview

10.1.2 Business overview

10.1.3Business strategies

10.2 Merck

10.2.1 Financial Overview

10.2.2 Business overview

10.2.3 Business strategies

10.3 Merial (Animal Health Division of Sanofi)

10.3.1 Financial Overview

10.3.2 Business overview

10.3.3 Business strategies

10.4 Elanco

10.4.1 Financial Overview

10.4.2 Business overview

10.4.3 Business strategies

10.5 Bayer Healthcare

10.5.1 Financial Overview

10.5.2 Business overview

10.5.3 Business strategies

10.6 Ceva Animal Health, Inc.

10.6.1 Financial Overview

10.6.2 Business overview

10.6.3 Business strategies

10.7 Virbac

10.7.1 Financial Overview

10.7.2 Business overview

10.7.3 Business strategies

10.8 Boehringer Ingelheim

10.8.1 Financial Overview

10.8.1 Business overview

10.8.1 Business strategies

11. Appendix

11.1. Abbreviations

11.2. Sources

11.3. Bibliography

11.4. Disclaimer

Content are not available

Choose License Type